Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988243 | 0.78 | IMPDH2 (0.50) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL3707241 | 0.78 | IMPDH2 (0.50) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL8530077 | 0.78 | IMPDH2 (0.50) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL16815127 | 0.74 | IKBKB (0.35) | IKBKBCHUKRIPK1GFERBRD4 | |
| SCHEMBL12585067 | 0.73 | XDH (0.64) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL28597933 | 0.73 | XDH (0.50) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL15388774 | 0.72 | AHR (0.47) | IKBKBCHUKRIPK1GFERALDH1A1 | |
| SCHEMBL21920740 | 0.71 | IMPDH2 (0.44) | IMPDH2IMPDH1XDHSLC22A12IKBKB | |
| SCHEMBL28600170 | 0.71 | AHR (0.45) | IKBKBCHUKRIPK1ALDH1A1CHEK1 | |
| SCHEMBL15934119 | 0.71 | TDP1 (0.38) | IKBKBCHUKKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197866-A1 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-19 | — | — | US | claimed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-118359634-A | Pyrazole derivative and medical use thereof | 正大天晴药业集团股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4297772-A1 | TREATMENT OF LIVER DISEASE WITH MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE (GPAM) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-116867510-A | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors | 雷杰纳荣制药公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| CN-113015526-A | Spirocyclic 2, 3-dihydro-7-azaindole compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| CN-105979950-A | Pyrrolotriazine kinase inhibitors | 百时美施贵宝公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3054955-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054358-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | IMPDH2 846/4885IMPDH1 694/4885XDH 2184/4885 |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | HIPK1, NEK1, HIPK2 | IMPDH2 846/4885IMPDH1 694/4885XDH 2184/4885 |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | AAK1, DAPK2, DAPK1 | IMPDH2 2951/4885IMPDH1 2948/4885XDH 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.